Overall vaccine effectiveness was 29% against COVID-19–associated hospitalization.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
The findings from 2 large clinical trials—one in the UK and one in Norway—discount the notion that vitamin D supplements protect against COVID-19 or other respiratory-tract infections.
Researchers in Taiwan have discovered a new mutation in the SARS-CoV-2 Omicron BA.2.3.7 subvariant that they suggest may be responsible for severe neurologic complications observed in young children on the island. Their study was published yesterday in the International Journal of Infectious Diseases.
Among a cohort who never had COVID-19 but tested positive within 1 year after baseline, depression, anxiety, stress, loneliness, and concerns about infection were linked to a 33% to 50% increased risk of self-reported postinfection symptoms lasting at least 4 weeks, as well as functional impairment, finds a study published today in JAMA Psychiatry.
Next week the WHO will publish 6 policy briefs that outline steps governments can take to reduce transmission and save lives.
Today JAMA Network Open published a study showing a 1.8% COVID-19 infection rate among in-person attendees at a February 2022 Academic Surgical Congress conference in Florida in which 100% of participants were vaccinated and 92% were boosted.
An estimated 10.5 million lost parents or caregivers to COVID-19, with 7.5 million orphaned.
A study of 346 previously healthy COVID-19 survivors finds that 73% had cardiac signs and symptoms more than 3 months after infection, and 57% still had them at nearly 1 year.
Low testosterone was tied to a 2.4-fold higher risk of hospital care with COVID-19.
Soon after vaccine advisors to the Centers for Disease Control and Prevention (CDC) yesterday voted to recommend updated COVID boosters that target the original virus plus the Omicron BA.4 and BA.5 subvariants, CDC Director Rochelle Walensky, MD, MPH, endorsed the Advisory Committee on Immunization Practices (ACIP) recommendation, paving the way for immunization to begin.
Experts voted 13-1 to approve both boosters, which target the original strain plus the latest subvariants.
